Cobicistat/darunavir/emtricitabine/tenofovir alafenamide - Janssen R&D Ireland

Drug Profile

Cobicistat/darunavir/emtricitabine/tenofovir alafenamide - Janssen R&D Ireland

Alternative Names: Cobicistat/darunavir/emtricitabine/GS 7340; Cobicistat/darunavir/emtricitabine/GS 7340 fixed-dose combination - Janssen; Darunavir/cobicistat/emtricitabine/GS-7340; Darunavir/emtricitabine/GS 7340/cobicistat; Emtricitabine/GS 7340/cobicistat/darunavir; GS 7340/cobicistat/darunavir/emtricitabine; SYMTUZA; Tenofovir alafenamide/cobicistat/darunavir/emtricitabine

Latest Information Update: 27 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences; Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen R&D Ireland
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Small molecules; Sulfonamides
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; HIV protease inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered HIV-1 infections

Most Recent Events

  • 27 Jul 2018 Interim efficacy and adverse events data from the phase III DIAMOND trial in HIV-1 infection released by Janssen Pharmaceutical
  • 17 Jul 2018 Registered for HIV-1 infections (Treatment-naive, Treatment-experienced, In adults) in USA (PO)
  • 17 Jul 2018 Updated adverse events data from the phase III AMBER trial in HIV-1 infections released by Janssen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top